ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

August 8, 1980

Long-Term Estrogen Use May Increase Ovarian Cancer Risk

April 27, 2001

Caribbean Conference Reports Incidence Differences With U.S.

August 22, 1986

NCAB Gives Final Approval to New Guidelines for P01s

May 29, 1987

World Conference To Consider Smoking Problem, Research, Action

March 14, 1975

Wanted: Methods To Measure Or Estimate Renal Function For Dosing Cancer Drugs

October 15, 2010